Retatrutide Research

Torricelli R, Kenny JE, Bache E, Pérez-Carbonell L, Huxford BF, Chohan H et al.

BackgroundHandwriting changes are recognised as an early manifestation of Parkinson's disease. Whilst isolated rapid eye movement sleep behaviour disorder (iRBD) is strongly associated with future Parkinson's diagnosis, changes in handwriting remain under-explored.ObjectiveTo assess the handwriti...

Gebreslase MN, Reta BK, Gebremariam AS, Zeray MA, Girmay HG, Gebretekle DM et al.

Primary peritoneal rhabdomyosarcoma is an exceedingly rare soft tissue malignancy in the pediatric population. Little is known about iatrogenic tumor cell peritoneal seeding after primary surgical resection of peritoneal rhabdomyosarcoma, and there is limited guidance on optimal management of suc...

Kanu C, Kimel M, Goetz I, Neff LM, Boye KS, Stefan M et al.

Obesity and overweight are associated with significant psychosocial burden. Existing patient-reported outcome (PRO) measures only assess a subset of emotion-related concepts that are relevant to individuals living with these conditions. The Weight and Emotions Scale (WES) was developed to enable ...

Zhang Y, Zhang C, Gong X, Cheng P, Fu H, Diao L et al.

To explore the association of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on heart rate (HR) in overweight or obese patients without diabetes.A comprehensive search of the PubMed, Web of Science, Embase, and Cochrane Library databases was conducted. Mean differences (MDs) were calculated...

Alavi SE, Boshrouyeh R, Raza A, Ebrahimi Shahmabadi H

Dual and triple incretin-based therapies are transforming treatment for type 2 diabetes mellitus, obesity, and non-alcoholic fatty liver disease. By targeting glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors, these agents enhance glycemic control, redu...

Ganamurali N, Sabarathinam S

Obesity has emerged as a global health crisis requiring innovative therapeutic strategies beyond conventional approaches. While glucagon-like peptide-1 (GLP-1) and dual GIP/GLP-1 receptor agonists have redefined pharmacological management, their limitations necessitate further innovation. Retatru...

Nanchen G, Pruijm M, Lamine F, Golshayan D, Fakhouri F

Complement inhibitors are expanding their indications in nephrology. In patients with type 2 diabetes, semaglutide prevents chronic kidney disease (CKD), while retatrutide reduces albuminuria in patients with diabetes and established CKD. Obinutuzumab improves the renal response in patients with ...

Pallavi K, Chandra A, Kumar K, Martand K, Sahu SS, Mohan L et al.

There are still substantial clinical challenges in treating patients who come with type 2 diabetes and/or obesity in addition to chronic kidney disease (CKD). Retatrutide, an innovative agent, represents a potential advancement in therapy; however, its performance and safety profile specifically ...

Raju P, Santhanam P, Prathiviraj R

The present study investigated the phylogenetic relationships among marine copepod populations in the coastal areas of Tamil Nadu and Pondicherry regions, India. Two molecular markers-a nuclear 18S rRNA gene and a mitochondrial COI gene-were evaluated for their accuracy and taxonomic resolution i...

Scotton WJ, Valentino RR, Martinez-Carrasco A, Real R, Macpherson HL, Tamvaka N et al.

Pick's disease (PiD) is a rare cause of sporadic frontotemporal dementia, neuropathologically defined by the presence of Pick bodies consisting of aggregates of 3-repeat tau. Given the genetic aetiology of PiD remains unresolved, we assembled the Pick's disease International Consortium (PIC) to i...

Elmendorf AJ, Yousefian M, Kim IM, Hardaway JA, Habegger K, Flak JN et al.

The epidemics of metabolic disease, in the form of obesity and type 2 diabetes, are a growing public health concern. However, incretin-based therapeutics have transformed our ability to address these diseases. While this current generation of incretin analogues show weight regain upon cessation o...

Guido G, Gulo B, Cotugno S, Nigussa W, Bobosha K, Segala FV et al.

Tuberculosis remains the leading cause of death by a single infectious agent globally, with Ethiopia among the highest tuberculosis- and human immunodeficiency virus/tuberculosis-burden countries. Diagnostic gaps-particularly among household contacts (HHCs) unable to expectorate-hinder early case...

GBD 2023 Lower Respiratory Infections and Antimicrobial Resistance Collaborators

Lower respiratory infections (LRIs) remain the world's leading infectious cause of death. This analysis from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 provides global, regional, and national estimates of LRI incidence, mortality, and disability-adjusted life-years...

Raza SS, Zakir Z, Hashmat A, Awan SK, Varrassi G

The global rise in obesity has accelerated both clinical and pharmaceutical innovation in antiobesity pharmacotherapy. This narrative review synthesizes current evidence on Food and Drug Administration-approved medications and emerging investigational agents that are shaping clinical practice. We...

Thunqvist E, Nygren Å, Löfman B, Parker D, Brulin E

The aim was to evaluate the effect of a Rehabilitation to Work (ReTA) model on symptoms of exhaustion disorder (ED), depression, and return to work (RTW) among healthcare workers on long-term sickness absence (LTSA) for stress-related ill-health.The ReTA was set up as a randomized control trial (...

Zheng Y, Wu Y, Chen J, Yang X, Zhang H, Yi Q et al.

Accurate segmentation of medical images is essential for various image processing tasks and is now predominantly achieved using deep learning techniques. However, existing approaches often employ loss functions that fail to account for pixel-level differences in prediction uncertainty or hardness...

Martínez-Castelao A, Górriz JL, Fernández-Fernández B, Soler MJ, Navarro-González JF

Diabetes mellitus (DM) continues to be a global world health problem. Despite medical advances, both DM and chronic kidney disease (CKD) remain global health issues with high mortality and limited options to prevent end-stage renal failure. Current therapies encompass five classes of drugs: (1) a...

Celletti E, Di Penta M, Ariani A, Parisi S, Andracco R, Raffeiner B et al.

The efficacy and safety of filgotinib (FIL) for the treatment of patients with rheumatoid arthritis (RA) have been evaluated in a number of randomized controlled trials. However, there is a scarcity of real-world studies evaluating the effectiveness, persistence, tolerability, and safety of FIL i...

Abdelrahman RM, Musa TH, Arbab IA, Suliman MH, Ahmed EO, Mohamed AN et al.

Obesity has emerged as a pressing global health challenge, and therapies based on glucagon-like Peptide 1 receptor agonists (GLP-1RAs) have transformed its management. Currently, liraglutide, semaglutide, and tirzepatide are FDA-approved for obesity treatment, while other agents are used off-labe...

Cohen CE, Fernandez S, Yaman U, Ehyaei AR, Porter T, O'Brien E et al.

Recent trials in Alzheimer's disease (AD) demonstrate encouraging outcomes. These trials target risk mechanisms identified through genetic analysis whilst directly aiming to reduce progression rates. Evidence from other neurodegenerative diseases suggests the genetics of progression is distinct f...